Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
In this large cohort of patients with TNBC-RD after NAC, omission of adjuvant therapy was common, with less than one-third of patients receiving adjuvant capecitabine. Receipt of adjuvant capecitabine was associated with significantly improved RFS, DRFS, and OS.
Authors
- V. Valero
- Qi Jin (ORCID: https://orcid.org/0000-0002-3638-8006)
- Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
- Ava Strahan (ORCID: https://orcid.org/0009-0007-0002-8758)
- Tonia Parker
- Ana C. Garrido-Castro (ORCID: https://orcid.org/0000-0002-5989-6636)
- Agepati S. Raghavendra (ORCID: https://orcid.org/0000-0002-7376-4947)
- S.M. Tolaney
- Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
- Carlos H. Bárcenas (ORCID: https://orcid.org/0000-0001-5377-9167)
- Timothy King
- Julie Vincuilla
- P. Tarantino
- Kai C. C. Johnson
- Melissa Grimm (ORCID: https://orcid.org/0009-0001-4244-7658)
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- Daniel G. Stover (ORCID: https://orcid.org/0000-0001-9003-8165)
- Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
- Danielle Brandes Zakon (ORCID: https://orcid.org/0000-0002-0532-5686)
- Mathew Cherian (ORCID: https://orcid.org/0000-0002-0380-2012)
- Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)
Institutions
- Twitter (United States) (US)
- Brigham and Women's Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105568
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00